"Nvidia Expands AI Drug Development with Amgen and Recursion Partnerships"
TL;DR Summary
Nvidia is expanding its partnerships with Amgen and Recursion Pharmaceuticals to further develop AI-powered drug discovery. Amgen's deCODE Genetics is building an Nvidia supercomputer to create genomics "foundation models," while Nvidia's BioNeMo platform for drug discovery is now in beta testing and being adopted by industry players. The pharmaceutical industry is increasingly turning to AI to improve the efficiency of drug discovery, although challenges such as data sharing and potential inaccuracies in AI-generated suggestions remain.
- Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships MarketWatch
- Generative AI Opening Next Era of Drug Discovery Nvidia
- Nvidia grows drug research footprint with Amgen, Recursion pacts FierceBiotech
- NVIDIA Corporation (NVDA) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Seeking Alpha
- Amgen to Build Generative AI Models for Drug Discovery Nvidia
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
87%
557 → 75 words
Want the full story? Read the original article
Read on MarketWatch